ß-Sitosterol activates autophagy to inhibit the development of hepatocellular carcinoma by regulating the complement C5a receptor 1/alpha fetoprotein axis.
Eur J Pharmacol
; 957: 175983, 2023 Oct 15.
Article
in En
| MEDLINE
| ID: mdl-37598926
Hepatocellular carcinoma (HCC) is highly refractory. ß-Sitosterol has been reported to suppress proliferation and migration as well as interfere with cell metabolism in tumors. However, there is limited information on the effects of ß-sitosterol on HCC. Herein, we used a xenograft mouse model to investigate the effects of ß-sitosterol on HCC tumor growth. The molecular mechanism was elucidated using quantitative real-time PCR, western blotting, lentiviral transfection, CCK8, scratch, Transwell, and Ad-mCherry-GFP-LC3B assays. The results showed that HepG2 cells highly expressed complement C5a receptor 1. ß-Sitosterol antagonized complement component 5a and exerted inhibitory effects on the proliferation and migration of HepG2 cells. The inhibitory effect of ß-sitosterol was reversed by the knockdown of complement C5a receptor 1. Bioinformatics analysis suggested alpha fetoprotein (AFP) as a downstream factor of complement C5a receptor 1. ß-Sitosterol inhibited AFP expression, which was reversed by complement C5a receptor 1 knockdown. The inhibitory effects of ß-sitosterol on cell proliferation and migration were weakened by AFP overexpression. Furthermore, ß-sitosterol induced autophagy in HepG2 cells, which was reversed by complement C5a receptor 1 knockdown and AFP overexpression. Blockade of autophagy by 3-MA attenuated ß-sitosterol inhibition of proliferation and migration in HepG2 cells. Moreover, ß-sitosterol inhibited HCC progression in vivo. Our findings demonstrate that ß-sitosterol inhibits HCC advancement by activating autophagy through the complement C5a receptor 1/AFP axis. These findings recommend ß-sitosterol as a promising therapy for HCC.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Eur J Pharmacol
Year:
2023
Document type:
Article
Affiliation country:
China
Country of publication:
Países Bajos